Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=81 A Study Designed to Evaluate Tear Production
Dry Eye Disease
Primary: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — 519.65 micrometers — p=<0.0001
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=55 TrueTear in Sjogren's Disease Patients
Dry Eye Syndromes · Sjogren's Syndrome
Primary: Schirmer Testing — 10.2; 0.8; 13.5 mm.
N/A N=47 Safety and Tolerability of Artificial Tears in Dry Eye Subjects
Dry Eye Syndrome
Primary: Tolerability Questionnaire Mean Scores at 1 Week — 70.1; 70.7; 57.3; 65.1 Scores on a scale
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
N/A N=316 Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score — 44; 45.2; -12.6; -13.6 Units on a scale
N/A N=20 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
Dry Eye Syndrome
Primary: Contrast Sensitivity — -0.375; -0.169; -0.313; -0.264 arbitrary units
Phase 3 N=623 Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Keratoconjunctivitis Sicca · Dry Eye
Primary: Change From Baseline in Eye Dryness Score as Measured by the VAS — -15.1; -20.6; -16.5 score on a scale — p=0.5533
Phase 3 N=40 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
Dry Eye Syndromes
Primary: Tear Evaporation Rate — 77.7; 67; 75.3 g/m^2*h
Phase 4 N=70 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2 — 56.06; 54.292; -27.048; -28.303 Scores on a Scale
Phase 2 N=76 A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
Meibomian Gland Dysfunction · Dry Eye
Primary: Meibomian Glands Yielding Liquid Secretion (MGYLS) — -0.7; 3.41; 3.07; 1.88 Number of Open Glands
Phase 3 N=80 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 4 N=51 Efficacy and Acceptability of Two Lubricant Eye Drops
Dry Eye Syndromes
Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day
N/A N=29 DAILIES TOTAL1® - Comparative Assessment of Tear Film Evaporation
Refractive Error
Primary: Tear Film Evaporation Rate — 120.88; 105.63 gm^-2 h
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
N/A N=288 Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects
Dry Eye Syndrome
Primary: Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90 — 2.7; 2.8; 2.8; -0.7 Scores on a Scale
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
N/A N=20 Acute Comfort of Lubricant Eye Drops FID 112903
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.1; 1.4 Units on a scale
N/A N=35 Evaluation of Ocular Comfort With ISTA Tears vs Systane
Dry Eye Disease
Primary: Percentage of Participants With Preference for One of the Treatments — 23; 1; 11 Participants
N/A N=48 A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Acute Stimulated Tear Production — 25.3; 9.2; 9.5 mm
Phase 4 N=15 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Glaucoma · Dry Eyes
Primary: Ocular Surface Staining — 1.65 units on a scale
N/A N=20 Acute Comfort of Lubricant Eye Drop FID 111421
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.7; 1.3 Units on a scale
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
Phase 2 N=138 Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants
Phase 4 N=55 Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients
Visual Acuity
Primary: Ocular Comfort — 81.96; 82.49 Units on a scale